Abstract: The disclosure provides a subspace-based blind identification algorithm of an ocean underwater acoustic channel for multi-channel fir filter, which adopts a technical solution that a channel impulse response coefficient is calculated by quadratic minimization. The disclosure has beneficial effects that estimation precision can be met when using a proper number of samples, and especially when a few noise vectors are used for estimating channel parameters, so that calculation amount is greatly reduced.

Abstract: The invention relates to prostate specific membrane antigen humanized antibodies (anti-PSMA) and anti-PSMA antibody drug conjugates. The invention also relates to methods and compositions for using anti-PSMA antibody drug conjugates in inhibiting, preventing or treating PSMA related diseases or cancers.

Abstract: The present invention discloses a system for real-time transmission of large-capacity of a deep-sea subsurface mooring based on a Beidou satellite. Data transmission is implemented by a mechanism of single module multi-card switching operation and dynamic subcontracting transmission. A receiving module is connected to a fixed card and is responsible for receiving state information on whether the transmission is successful. A subsurface mooring end antenna and a land-based antenna adopt a network analyzer to perform secondary matching on parameters such as frequency offset and impedance of the assembled antenna, and effectively intercept original data. In addition, arithmetic coding and dictionary coding are adopted for data compression. While an acquisition board terminal processes original valid data, the valid data is compressed to a maximum of one third of the original data, which can be extended into a parallel mode of multiple single-mode multi-card modules.

Abstract: A flexible photonic skin is provided, including a functional layer, an adhesive layer used for fixing the functional layer and made of hypoallergenic polyvinyl ethyl ether, and a packaging layer made of a polyurethane semi-transparent film and adhered to the adhesive layer, which are arranged successively from the top down, wherein the functional layer consists of two electrodes located on two sides and used for acquiring electrocardiographic signals of a human body, and a polymer-based photonic integrated chip located between the two electrodes and used for acquiring body temperature, pulse, blood pressure and blood glucose signals of the human body; and, the polymer-based photonic integrated chip processes and outputs the acquired electrocardiographic signals of the human body as well as the body temperature, pulse, blood pressure and blood glucose signals of the human body.

Abstract: The present invention relates to a potential difference-based diversion electrode arrangement and field intensity compensation method, comprising the following steps: the arrangement positions of paired diversion electrodes are determined according to the difference of potential around a position of field intensity to be compensated and the direction of an electric field line, and the paired diversion electrodes are inserted; and the field intensity enhancement rate of the position of field intensity to be compensated and the compensated field intensity value are calculated according to the difference of potential and arrangement positions of the paired diversion electrodes.

Abstract: The present invention relates to 2?-Fluoro-b?-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses, especially HBV.

Abstract: Antibody drug conjugates (ADCs) comprising an antibody conjugated to an anti-inflammatory therapeutic agent via a phosphate-based linker with tunable extracellular and intracellular stability are described.

Abstract: A Pseudomonas sp. ECO-1 strain was preserved at the China General Microbiological Culture Collection Center (CGMCC) on Mar. 31, 2017, with the preservation number of CGMCC No. 13960. The Pseudomonas sp. ECO-1 strain was separated from POPs (Persistent Organic Pollutants) polluted soil for the first time. The bifunctional enzyme preparation capable of efficiently degrading polychlorinated biphenyl and atrazine was prepared by utilizing the strain for the first time; especially, the bifunctional enzyme preparation has remarkable degradation activity on the polychlorinated biphenyl which is difficult to degrade under an aerobic condition, which is completely different from functions of existing known Pseudomonas sp. and enzyme preparations thereof.

Abstract: Phosphate-based linkers with tunable stability for intracellular delivery of drug conjugates are described. The phosphate-based linkers comprise a monophosphate, diphosphate, triphosphate, or tetraphosphate group (phosphate group) and a linker arm comprising a tuning element and optionally a spacer. A payload is covalently linked to the phosphate group at the distal end of the linker arm and the functional group at the proximal end of the linker arm is covalently linked to a cell-specific targeting ligand such as an antibody. These phosphate-based linkers have a differentiated and tunable stability in blood vs. an intracellular environment (e.g. lysosomal compartment).

Abstract: The present invention relates to 2?-Fluoro-6?-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses, especially HBV.

Abstract: A Pseudomonas sp. ECO-1 strain was preserved at the China General Microbiological Culture Collection Center (CGMCC) on Mar. 31, 2017, with the preservation number of CGMCC No. 13960. The Pseudomonas sp. ECO-1 strain was separated from POPs (Persistent Organic Pollutants) polluted soil for the first time. The bifunctional enzyme preparation capable of efficiently degrading polychlorinated biphenyl and atrazine was prepared by utilizing the strain for the first time; especially, the bifunctional enzyme preparation has remarkable degradation activity on the polychlorinated biphenyl which is difficult to degrade under an aerobic condition, which is completely different from functions of existing known Pseudomonas sp. and enzyme preparations thereof.

Abstract: A method of preparing collagen active peptides with antiproliferative activity against cancer cells. The collagen active peptides are obtained by hydrolysis of papain and trypsin and a specific purifying process. The collagen active peptides have antiproliferative activity against cancer cells, such as ovarian carcinoma cells including SKOV3, OVCAR3, 436 and SRO82 and the prostate cancer cells including PC3, LnCAPC1, and LnCAPC2.

Abstract: The present invention relates to 2?-Fluoro-6?-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses, especially HBV.

Abstract: The present invention relates to a potential difference-based diversion electrode arrangement and field intensity compensation method, comprising the following steps: the arrangement positions of paired diversion electrodes are determined according to the difference of potential around a position of field intensity to be compensated and the direction of an electric field line, and the paired diversion electrodes are inserted; and the field intensity enhancement rate of the position of field intensity to be compensated and the compensated field intensity value are calculated according to the difference of potential and arrangement positions of the paired diversion electrodes.

Abstract: A method of preparing collagen active peptides with antiproliferative activity against cancer cells. The collagen active peptides are obtained by hydrolysis of papain and trypsin and a specific purifying process. The collagen active peptides have antiproliferative activity against cancer cells, such as ovarian carcinoma cells including SKOV3, OVCAR3, 436 and SRO82 and the prostate cancer cells including PC3, LnCAPC1, and LnCAPC2.

Abstract: The present invention relates to 2?-Fluoro-6?-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Hepatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses, especially HBV.

Abstract: Phosphate-based linkers with tunable stability for intracellular delivery of drug conjugates are described. The phosphate-based linkers comprise a monophosphate, diphosphate, triphosphate, or tetraphosphate group (phosphate group) and a linker arm comprising a tuning element and optionally a spacer. A payload is covalently linked to the phosphate group at the distal end of the linker arm and the functional group at the proximal end of the linker arm is covalently linked to a cell-specific targeting ligand such as an antibody. These phosphate-based linkers have a differentiated and tunable stability in blood vs. an intracellular environment (e.g. lysosomal compartment).

Abstract: Described herein are compounds and compositions for treating drug resistant and persistent tuberculosis. Also described herein is a method of screening for identifying biofilm formation inhibitors.

Abstract: The present invention relates to 2?-Fluoro-6?-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Hepatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses.

Abstract: The present invention relates to 2?-Fluoro-6?-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses.